Vanguard Group Inc. Buys 693,852 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Vanguard Group Inc. grew its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 40.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,400,142 shares of the company’s stock after buying an additional 693,852 shares during the quarter. Vanguard Group Inc. owned 8.51% of Krystal Biotech worth $278,416,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Commonwealth Equity Services LLC grew its stake in shares of Krystal Biotech by 2.5% during the third quarter. Commonwealth Equity Services LLC now owns 4,426 shares of the company’s stock valued at $513,000 after buying an additional 110 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in Krystal Biotech by 50.0% in the second quarter. PNC Financial Services Group Inc. now owns 372 shares of the company’s stock worth $44,000 after buying an additional 124 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Krystal Biotech by 1.8% in the fourth quarter. The Manufacturers Life Insurance Company now owns 8,485 shares of the company’s stock worth $672,000 after buying an additional 150 shares during the period. Legal & General Group Plc lifted its holdings in Krystal Biotech by 2.2% in the fourth quarter. Legal & General Group Plc now owns 7,120 shares of the company’s stock worth $564,000 after buying an additional 155 shares during the period. Finally, State of Wisconsin Investment Board lifted its holdings in Krystal Biotech by 0.9% in the second quarter. State of Wisconsin Investment Board now owns 16,727 shares of the company’s stock worth $1,964,000 after buying an additional 156 shares during the period. 86.29% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the sale, the insider now owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the sale, the insider now owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Kathryn Romano sold 5,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total transaction of $829,400.00. Following the sale, the chief accounting officer now directly owns 12,936 shares of the company’s stock, valued at approximately $2,145,823.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 40,587 shares of company stock valued at $6,535,591. Company insiders own 17.00% of the company’s stock.

Krystal Biotech Stock Up 0.4 %

Shares of NASDAQ KRYS opened at $177.93 on Friday. Krystal Biotech, Inc. has a twelve month low of $77.10 and a twelve month high of $189.97. The firm has a market cap of $5.03 billion, a P/E ratio of 2,224.40 and a beta of 0.86. The company has a 50 day moving average of $141.67 and a 200 day moving average of $123.87.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.82. The firm had revenue of $42.14 million during the quarter, compared to analysts’ expectations of $27.43 million. During the same quarter in the previous year, the firm earned ($1.25) earnings per share. As a group, equities analysts expect that Krystal Biotech, Inc. will post 1.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on KRYS shares. Cantor Fitzgerald raised their price objective on shares of Krystal Biotech from $160.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, December 13th. Guggenheim lifted their target price on shares of Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. William Blair reiterated an “outperform” rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Finally, Citigroup lifted their target price on shares of Krystal Biotech from $160.00 to $195.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $157.67.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).